Back to top

zacks-consensus-estimate: Archive

Zacks Equity Research

AZZ (AZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AZZ (AZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Franklin Covey (FC) Expected to Beat Earnings Estimates: Should You Buy?

Franklin Covey (FC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Constellation Brands (STZ) Q3 Earnings Expected to Decline

Constellation Brands (STZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Jefferies (JEF) to Report a Decline in Earnings: What to Look Out for

Jefferies (JEF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Kura Sushi (KRUS) Q1 Earnings Expected to Decline

Kura Sushi (KRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Does Daktronics (DAKT) Have the Potential to Rally 29.17% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Daktronics (DAKT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Wall Street Analysts See a 60.47% Upside in Ooma (OOMA): Can the Stock Really Move This High?

The mean of analysts' price targets for Ooma (OOMA) points to a 60.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Wall Street Analysts See a 68.54% Upside in WeRide Inc. (WRD): Can the Stock Really Move This High?

The consensus price target hints at a 68.5% upside potential for WeRide Inc. (WRD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Why This 1 Business Services Stock Could Be a Great Addition to Your Portfolio

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.